SPONSOR
Alnylam Pharmaceuticals
Total Trials
4
Recruiting
4
Phases
Phase 2, Phase 1, Phase 1, Phase 2
Conditions studied: Cerebral Amyloid AngiopathyAdvanced Hepatocellular CarcinomaMetastatic Hepatocellular CarcinomaAcute Hepatic PorphyriaHereditary Hemorrhagic Telangiectasia
Alnylam Pharmaceuticals is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including Cerebral Amyloid Angiopathy, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Acute Hepatic Porphyria.
The trial portfolio spans Phase 2, Phase 1, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Alnylam Pharmaceuticals
How many clinical trials has Alnylam Pharmaceuticals sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by Alnylam Pharmaceuticals, of which 4 are actively recruiting participants. These trials cover conditions including Cerebral Amyloid Angiopathy, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Alnylam Pharmaceuticals research focus on?
Alnylam Pharmaceuticals clinical trials span Cerebral Amyloid Angiopathy, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Acute Hepatic Porphyria, Hereditary Hemorrhagic Telangiectasia. The research pipeline includes Phase 2, Phase 1, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Alnylam Pharmaceuticals clinical trial?
To participate in a Alnylam Pharmaceuticals trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Alnylam Pharmaceuticals trials with current recruitment status updated daily.
Clinical Trials by Alnylam Pharmaceuticals
NCT06393712 Phase 2
Recruiting
A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
NCT06600321 Phase 1
Recruiting
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
NCT04883905
Recruiting
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
Acute Hepatic Porphyria
NCT06659640 Phase 1, Phase 2
Recruiting
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Hereditary Hemorrhagic Telangiectasia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology